6505--Rituximab and Biosimilars

The Department of Veterans Affairs National Acquisition Center is seeking to establish a supply source for Rituximab 10mg/mL and its biosimilars through this solicitation. The procurement targets two specific line items: Rituximab in 10mL vials (17,858 annually) and 50mL vials (25,111 annually), with a single award planned to cover both items. Proposals are due March 11, 2025, at 2:30 PM CT, with the base ordering period scheduled to commence September 15, 2025, following a potential 60-day implementation period. Contractors must submit pricing that includes a 0.5% Cost Recovery Fee and maintain business agreements with Pharmaceutical Prime Vendor (PPV) contractors. Products must be FDA-approved, possess appropriate NDC numbers, comply with Drug Supply Chain Security Act requirements, and include barcode labeling.

The solicitation is unrestricted but requires large businesses to submit a small business subcontracting plan. Authorized users for this contract include VA facilities, Department of Defense facilities, Indian Health Service, Bureau of Prisons, Federal Health Care Center, and Option 2 State Veterans Homes. The contract structure includes a base year with four additional one-year option periods. While specific award values are not detailed, the procurement covers significant annual quantities of pharmaceutical products. Performance will be distributed through VA and DoD Pharmaceutical Prime Vendor Programs, with products to be supplied nationwide to the authorized user organizations. The procurement falls under NAICS Category 325412 (Pharmaceutical Preparation Manufacturing) and PSC Category 6505 (Drugs and Biologicals), indicating a specialized pharmaceutical supply contract.